
Novo Nordisk has named the person who will henceforth lead the pharmaceutical firm's unit for Global Drug Discovery, where new drugs are developed in early stages.
As Marcus Schindler takes over the role of chief scientific officer and executive vice president of research and early development after Mads Krogsgaard's Thomsen, this position has become vacant.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app